Biomea Fusion (BMEA) Stock Overview
A clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Risk Analysis
BMEA passed our risk checks.
BMEA Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Biomea Fusion, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.51 |
| 52 Week High | US$12.85 |
| 52 Week Low | US$1.29 |
| Beta | -0.14 |
| 1 Month Change | -22.96% |
| 3 Month Change | -18.38% |
| 1 Year Change | -87.04% |
| 3 Year Change | -83.44% |
| 5 Year Change | n/a |
| Change since IPO | -91.88% |
Recent News & Updates
Biomea Fusion: Surging On Data, Sinking On Funding - I'm On The Sidelines
Oct 07Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?
Aug 17
Recent updates
Biomea Fusion: Surging On Data, Sinking On Funding - I'm On The Sidelines
Oct 07Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?
Aug 17We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
Sep 30We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully
Jun 10We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth
Feb 22Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?
Nov 07We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully
Jul 12Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation
Mar 29We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely
Nov 03Biomea Fusion GAAP EPS of -$0.59 beats by $0.01
Aug 01We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
Jul 20Shareholder Returns
| BMEA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.1% | 0.4% | -1.5% |
| 1Y | -87.0% | -0.7% | 14.4% |
Price Volatility
| BMEA volatility | |
|---|---|
| BMEA Average Weekly Movement | 13.7% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 63 | Mick Hitchcock | biomeafusion.com |
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It’s lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.
Biomea Fusion, Inc. Fundamentals Summary
| BMEA fundamental statistics | |
|---|---|
| Market cap | US$112.42m |
| Earnings (TTM) | -US$112.09m |
| Revenue (TTM) | n/a |
Is BMEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BMEA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$112.09m |
| Earnings | -US$112.09m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.59 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BMEA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/17 23:21 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biomea Fusion, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Naureen Quibria | Capital One Securities, Inc. |
| Yigal Nochomovitz | Citigroup Inc |
| Jason Kolbert | D. Boral Capital LLC. |